Research Papers:

Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma

Huan Zhao, Tian Qiu, Huiqin Guo, Jianming Ying, Junling Li and Zhihui Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:106685-106692. https://doi.org/10.18632/oncotarget.22530

Metrics: PDF 1145 views  |   HTML 1717 views  |   ?  


Huan Zhao1,*, Tian Qiu1,*, Huiqin Guo1, Jianming Ying1, Junling Li2 and Zhihui Zhang1

1Department of Pathology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2Department of Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

*These authors contributed equally to this work

Correspondence to:

Zhihui Zhang, email: [email protected]

Junling Li, email: [email protected]

Keywords: EGFR; KRAS; lung cancer; adenocarcinoma; fine-needle aspiration

Received: May 17, 2017     Accepted: October 25, 2017     Published: November 20, 2017


Background: The detection of EGFR and KRAS mutations of metastatic lung adenocarcinoma using liquid-based cytology suspension routine specimens from fine-needle aspiration remains controversial.

Results: The DNA of all specimens was extracted and real time PCR was performed successfully. The rate of EGFR and KARS mutations was 37.7% (58/154) and 5.8% (9/154), respectively. EGFR mutation rate was significantly higher in females than that in males (47.8% vs. 29.4%, P = 0.019). There were no significant differences among different age groups or different tumor sites. These results of EGFR and KRAS mutations using LBC specimens were consistant with the tissue samples. In 30 patients treated with tyrosine kinase inhibitors, complete response, partial response, stable disease and progress disease was observed in 2, 10, 13 and 5 patients, respectively.

Conclusions: Liquid-based cytology specimen is reliable and can be an alternative source for the detection of EGFR and KRAS mutations.

Methods: 154 fine-needle aspiration cytologic samples were obtained from patients with metastatic lung adenocarcinoma. The specimens included 21 cases of mediastinal lymph node 123 cases of neck nodules and 10 cases of subcutaneous nodules. After the diagnosis and count of tumor cells performed by cytopathologists, liquid-based cytology specimens with sufficient tumor cells were used for EGFR and KRAS testing using real-time PCR.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22530